IL-15 mediated expansion of rare durable memory T cells following adoptive cellular therapy
Abstract
Synovial sarcoma (SS) and myxoid/round cell liposarcoma (MRCL) are ideal solid tumors for the development of adoptive cellular therapy (ACT) targeting NY-ESO-1, as a high frequency of tumors homogeneously express this cancer-testes antigen. Data from early phase clinical trials have shown antitumor activity after the adoptive transfer of NY-ESO-1–specific T cells. In these studies, persistence of NY-ESO-1 specific T cells is highly correlated with response to ACT, but patients often continue to have detectable transferred cells in their peripheral blood following progression.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- May 01, 2021
- Source ID
- 10.1136/jitc-2020-002232
Entities
People
- Antoni Ribas
- Brett A Schroeder
- Cassian Yee
- Dawn Stief
- Douglas S. Hawkins
- Edward Y. Kim
- Erik A Farrar
- Heather Sloan
- Jean S Campbell
- Jianhong Cao
- Karan Kohli
- Lee D Cranmer
- Michael J. Wagner
- Ralph Graeme Black
- Robert Hamilton Pierce, MD
- Robin L Jones
- Seth M Pollack
- Shihong Zhang
- Stanley R Riddell
- Theodore Scott Nowicki
- Venu G Pillarisetty
- Yao Lu
Organizations
- National Cancer Institute
- United States Department of Defense